Patients may not be receiving investigational agents at time of registration, or at any time while on study and during the 4 weeks preceding enrollment
Participants should not have received any other investigational agents nor have participated in an investigational trial within the past 4 weeks
Use of any other investigational or study agents
Use of investigational cancer agents within 6 weeks prior to diagnosis
Patients must not receive any other investigational agents while on study or within four weeks prior to registration
Other anticancer agents and investigational agents should not be given while the subject is on study treatment
Patients must not have received radiation therapy, non-cytotoxic agents or investigational agents or systemic corticosteroids within 14 days prior to registration
Investigational agents from previous clinical study within 4 weeks
Prior receipt of any investigational immunotherapy. Subjects may have received agents that have local health authority approval for the disease indication
Participants cannot receive treatment with any other investigational agents during protocol therapy
No chemotherapy, other investigational agents within 14 days of study treatment
Patients may not have received any other investigational agents within the last 14 days at the time of treatment start
Exposure to any other anti-leukemic therapy (except hydroxyurea) within 2 weeks before the first dose of study treatment (including investigational chemotherapy regimens involving approved agents)
Current or anticipated use of other investigational agents during the study
Receiving other investigational agents or not yet completed 30 days since completion of an investigational study
Subjects may not be receiving any investigational agents within 30 days prior to start of study treatment
Patients must not have ongoing treatment with any other investigational agents =< 14 days prior to registration
No other investigational, biologic or chemotherapy agents, localized ablation or chemoembolization for 4 weeks prior to study entry
Patients who are receiving any other investigational or chemotherapeutic agents will be excluded; please contact the study principal investigator (PI) if a patient has received an investigational or chemotherapeutic agent in the past
Participant has used investigational agents within 4 weeks of randomization.
Prior treatment with FR-targeting investigational agents is not allowed
Participant receiving any other investigational agents within 30-days of enrollment nor during study participation
Patients may not be receiving any other investigational agents; (i.e. 28-day washout period from prior investigational drug is required)
Current or anticipated use of other investigational agents or marketed anticancer agent while on study
Current enrollment in another clinical study involving treatment and/or is receiving an investigational agent for any reason, or use of any investigational agents within 14 days of initiating study treatment.
Receipt of any chemotherapy, biological therapy or investigational agents within 3 weeks prior to study registration
Other investigational agents: ?4 weeks
No use of investigational agents within 4 weeks of study enrollment or use of immunosuppressive or immunomodulating agents within 8 weeks of study entry
Patients who had therapy with one of the investigational agents more than 1 month prior to enrollment in whom tumor genotyping show assignment to the same investigational agent
Subjects may not receive any other concomitant investigational agents
Subjects who are receiving any other investigational agents. Prior immunotherapy, topotecan and temozolomide are allowed
Prior treatment with folate receptor (FR) targeting investigational agents is allowed for dose escalation provided that such treatment was not discontinued due to adverse events; prior FR-targeting investigational agents are not allowed for patients in the expansion cohort
Subjects who require warfarin, anti-cancer therapeutics or investigational agents
Treatment with any investigational antileukemic agents or chemotherapy agents in the last 7 days before study entry, unless full recovery from side effects has occurred or patient has rapidly progressive disease judged to be life-threatening by the investigator
Chemotherapy, small molecule inhibitors, radiation, and/or other investigational anticancer agents (excluding investigational monoclonal antibodies): 2 weeks.
Participants who received investigational agents, other than investigational antiretroviral agents for HIV, within the 4 weeks before randomization, unless approved by the study chair
Use of any other investigational agents within 30 days of starting study treatment
Administration of investigational agents within 28 days prior to treatment initiation
Current or anticipated use of other investigational agents
Prior BCMA-directed investigational agents at any time
Treatment with any investigational antileukemic agents or chemotherapy agents in the last 7 days before study entry, unless full recovery from side effects has occurred or patient has rapidly progressive disease judged to be life-threatening by the investigator.
Treatment with any investigational antileukemic agents or chemotherapy agents in the last 7 days before study entry, unless full recovery from side effects has occurred or patient has rapidly progressive disease judged to be life-threatening by the investigator.
Patients may not be receiving any other investigational agents; a 2 week wash-out period for investigational agents is required before registration
Concomitant use of other investigational agents.
Any previous treatment with a DDR agent, including any of the investigational agents
No investigational agents within 2 weeks prior to first study treatment.
Patients receiving any other investigational agents; any prior investigational agents must be stopped at least 14 days (2 week washout) prior to registration
Patients should not have received any other investigational agents within the past 4 weeks
Receipt of Investigational agents within 28 days prior to first dose of protocol therapy.
Subjects must not have had any prior investigational agents or devices within 4 weeks of beginning study drug
Treatment with other investigational agents within 30 days of day 1
Previous immunotherapy or investigational agents within 6 months of first administration of study drug
Patients are permitted to receive investigational imaging agents while on study
Previous immunotherapy or investigational agents within 6 months of first administration of study drug
Patients receiving any other investigational agents or whom have received recent treatment for colorectal cancer (radiation within the previous two weeks, chemotherapy or investigational therapy within the previous four weeks)
Patients receiving any other investigational chemotherapeutic agents within 28 days prior to the first dose of trial treatment
Subjects receiving any other investigational or standard antineoplastic agents
Receipt of any other investigational agents within 14 days prior to study treatment
Use of any investigational agents within 21 days of registration.
Current or anticipated use of other investigational agents; NOTE the following clarification for this study:\r\n* Prohibited concurrent therapy: \r\n** Participation in clinical trials with other investigational agents, not included in this trial, within 14 days of the start of this trial until 2 weeks after subject has received the last dose of bortezomib for mobilization\r\n** Hypersensitivity to bortezomib, boron or mannitol or G-CSF
Use of any of the following after transplantation and prior to starting study therapy for cohort 3:\r\n* Investigational agents/therapies\r\n* Anti-leukemic agents given as post-transplant maintenance therapy (e.g., subcutaneous or oral 5-azacytidine or FLT3 inhibitors for maintenance)
Use of any active treatment for relapse/refractory AML including but not restricted to chemotherapy, targeted agents, hypomethylating agents or investigational drugs; use of hydroxyurea up to 6g per day for cytoreduction is allowed for a maximum of 15 days prior treatment
Participation in any other investigational study or use of any other investigational agents within 30 days prior to study entry
JUST PRIOR TO FIRST VACCINATION (WITHIN 21 DAYS): patients may not be receiving any other investigational agents
At least 3 weeks must have passed since any of the following: systemic corticosteroids, immunotherapy (for example, T-cell infusions, immunomodulatory agents, interleukins, MCC vaccines, intravenous immunoglobulin, expanded polyclonal tumor infiltrating lymphocytes [TIL] or lymphokine-activated killer [LAK] therapy), pentoxifylline, other small molecule or chemotherapy cancer treatment, other investigational agents or other systemic agents that target Merkel cell carcinoma
Subjects must not have received any investigational agents within 30 days of study entry
Subjects requiring or using other investigational agents while on treatment in this trial.
Participants receiving any other investigational or commercial agents or therapies administered with the intention to treat their malignancy within 30 days from first receipt of study drug
Use of any investigational agents within 30 days prior to enrollment and for the duration of the study
Subjects may have received any other investigational agents or chemotherapy as long as they are eligible for SABR and surgery
Current therapy with any other investigational agents.
Current or anticipated use of other investigational agents
Chemotherapeutic agents for therapy of AML (note that prophylactic use of these agents is allowed in this study, e.g., methotrexate for GVHD)
Investigational agents/therapies
Past history of other investigational agents
Patients may not be receiving any other investigational agents with the intent to treat the disease (imaging agents are acceptable)
Treatment with chemotherapy, monoclonal antibodies or biological agents (e.g. lenalidomide) other than the investigational agents during the time of participation in this trial
Current use (or planned use during the treatment period) of other investigational agents, or biological, chemotherapy, radiation or other anti-tumor therapy
Investigational compound within 4 weeks of enrollment or who are planning to receive other investigational agents while participating in this study
Patients must not have received other investigational agents within 14 days of initiation of the conditioning regimen
Ongoing use of investigational agents or use of investigational agents within the last four weeks
Are being treated with other investigational agents.
Subjects receiving any other investigational or standard antineoplastic agents
Patients must not have received any investigational agents within 21 days of study entry
Must not be receiving any other investigational agents within 14 days of first dose of azacitidine (day 7)
Treatment with any investigational antileukemic agents or chemotherapy agents in the last 7 days before study entry, unless full recovery from side effects has occurred or patient has rapidly progressive disease judged to be life-threatening by the investigator
Prior chemotherapy, small molecule inhibitors, and/or other investigational anticancer agents (excluding investigational monoclonal antibodies) within 4 weeks
-  Investigational Agents: Investigational agents within 4 weeks (or 5 half-lives) of PV-10 administration.
Simultaneous primary invasive cancers or patients currently receiving any other investigational agents at time of study enrollment. Patients may have received investigational agents in the past. No washout time period is required.
Subject has received other investigational agents or devices within 28 days prior to first dose of study treatment.
Prior or current use of any investigational or commercially available anti-HCV agents other than interferon or ribavirin or receipt of any investigational product within 6 weeks prior to study drug administration
Current receipt of any other investigational agents
Previous treatment with any other investigational agents within 4 weeks prior to MCLA-117 administration;
Patients receiving any other investigational agents or anti-cancer agents within 30 days other than mibefradil dihydrochloride, hypofractionated RT, or corticosteroids as described in this clinical protocol during treatment
No use of investigational agents within 4 weeks of study enrollment or use of immunosuppressive or immunomodulating agents (including intravenous immunoglobulin [IVIG]) within 8 weeks of study entry; note: use of topical, inhaled and intranasal steroid therapy is permitted
no current or prior use of investigational agents within 4 weeks of study entry.
No non-approved investigational agents or procedures ?4 weeks of study entry
Prior treatment with non-chemotherapy investigational agents is permitted
Use of other investigational agents within 6 months prior to enrollment
Concomitant use of other investigational agents
Receiving any other investigational agents within 4 weeks of beginning study treatment
Subjects receiving any other investigational or standard antineoplastic agents
Patients who have received any other investigational agents within the preceding 4 weeks
Treatment with other investigational agents within 30 days of day 1
No investigational agents within 4 weeks from initiation of study treatment
Patients must not receive any other investigational agents while on study or within four weeks prior to randomization
Current or anticipated use of other investigational agents
DOSE EXPANSION COHORT: Current or anticipated use of other investigational agents while participating in this study
Subjects must not have received any investigational agents within 30 days of study entry
Therapy with other investigational agents within 4 weeks of treatment initiation on this trial
Any other investigational agents within the past 4 weeks
Ongoing use of any other investigational or study agents
Patients may not be receiving or have received any other  investigational agents during or within 1 month prior to treatment with NFV
Current or anticipated use of other investigational agents
Patients who have received any other investigational agents within the last 4 weeks
Patients must NOT be receiving any other investigational agents concurrently and must not have received any other investigational agents =< 4 weeks prior to registration
PHASE II: Patients must NOT be receiving any other investigational agents concurrently and must not have received any other investigational agents =< 4 weeks prior to randomization
Patients may not be receiving any other investigational agents within 4 weeks of starting the study treatment and during the study period
Patients must not receive any other investigational agents during the period on study or the four weeks prior to entry
Current use of any investigational agents
Patients may not be receiving any other investigational agents at time of study entry or at any time while on study or be on another investigational agent that can impact on the primary clinical outcome analyses or has known pharmacodynamics or pharmacokinetic effects on AAT
Treatment with other investigational agents
Patients must not be planning to receive any other investigational agents during the course of protocol treatment
Chemotherapy, small molecule inhibitors, radiation, and/or other investigational anticancer agents (excluding investigational monoclonal antibodies): 2 weeks
Active treatment with any other investigational agents
Patients may not be planning to receive any other investigational agents
Patients must not be planning to receive other anti-cancer agents including investigational agents while on protocol treatment
Use of cytotoxic, chemotherapeutic, targeted or investigational agents/therapies, thrombopoiesis-stimulating agents (TSAs), erythropoiesis-stimulating agents (ESAs) and other red blood cell hematopoietic growth factors, and within 28 days prior to randomization
Received other investigational agents within 30 days prior to the start of the conditioning regimen
Patients must not have used cytotoxic chemotherapeutic agents or experimental agents (agents that are not commercially available) for the treatment of MDS within 8 weeks of randomization
Patients may not have received any other investigational agents within 4 weeks of study entry
Subject who is receiving or has received any other investigational agents within 28 days prior to day 1 of treatment in this study; in addition, day 1 of the study treatment should be at least 14 days after prior chemotherapy
Patients with any number of prior therapies with anti-angiogenic agents or immunotherapy with the exception of any previous anti-CTLA-4 directed agents are allowed; a 2 week washout period is required for all agents, except for bevacizumab where a 4 week washout is required
Subjects who are receiving or have received any other investigational agents within 28 days prior to day 1 of treatment in this study
Concomitant use of other investigational agents
Current or anticipated use of other investigational agents
Current or past use of investigational agents within 4 weeks of study enrollment
Other investigational agents within 21 days prior to study treatment.
Use of any other investigational agents
Current use of other investigational agents
Use of investigational agents within 30 days
Receipt of any other investigational agents within 4 weeks preceding the start of study treatment
Patients may not be receiving any other investigational agents\r\n* Note: a wash-out period of 2 weeks prior to registration is required for any patient to be enrolled in the study
Use of any other investigational agents
Participants should not have received any other investigational agents nor have participated in an investigational trial within the past 4 weeks
Prior investigational agents =< 4 weeks prior to registration
Use of investigational agents of any kind within 30 days before study treatment
Previous treatment with a camptothecin derivative (eg., irinotecan, topotecan, and investigational agents including but not limited to exatecan, rubitecan, gimatecan, karenitecan, SN38 investigational agents, EZN 2208, SN 2310, and AR 67) is not allowed
Treatment with chemotherapy, monoclonal antibodies, biological agents (e.g. Ibrutinib) or other than the investigational agents during the time of participation in this trial
Other investigational agents =< 4 weeks prior to registration/ randomization
At least 3 weeks since prior biologics or investigational agents
Prior use of other investigational agents to treat the brain tumor
Current or prior treatment for this cancer with immunotherapy and/or any other investigational agents
Current or anticipated use of other investigational agents while participating in this study
Receipt of any other investigational agents within 14 days prior to study enrollment
Anti-tumor therapy (i.e. chemotherapeutics or investigational agents or immunotherapy) within 4 weeks prior to enrollment
Treatment with other investigational agents =< 14 days of registration
Participants may not be receiving any other investigational or commercial agents or therapies other than those described in this protocol to treat their malignancy
Use of cytotoxic chemotherapeutic agents, or experimental agents (agents that are not commercially available) for the treatment of CMML within 28 days of the first day of study drug treatment
Treatment with other investigational agents (defined as not used in accordance with the approved indication) within 4 weeks of Day 1
Patient must not have received any other investigational agents within 14 days prior to study enrollment
Exposure to chemotherapy, radiotherapy, biologics or investigational agents within 3 weeks prior enrollment in the study
Current or anticipated use of other investigational agents
Subjects receiving other investigational agents thirty days prior to study treatment or during treatment
Patients may not be receiving any other investigational agents; any prior investigational products must be stopped at least 14 days (2-week washout) prior to registration
Subjects may not receive any other concomitant investigational agents
Treatment with other investigational agents in the prior 4 weeks.
Use of investigational agents within 4 weeks prior to enrollment
Any investigational agents
Treatment with other investigational agents within 30 days of day 1
Patients who are using other investigational agents or who had received investigational drugs =< 4 weeks prior to study treatment start
Receiving any other investigational agents including those for symptom management
Patients must not have received any other investigational agents within 30 days prior to vaccination.
Treatment with any investigational antileukemic agents or chemotherapy agents in the last 7 days before study entry, unless full recovery from side effects has occurred or patient has rapidly progressive disease judged to be life-threatening by the investigator
Immunomodulatory agents within 7 days
Patients who are receiving any other investigational agents or commercial agents with the intent to treat the malignancy
Other investigational agents: ?4 weeks
Current use (or planned use during the treatment period) of other investigational agents, or biological, chemotherapy, radiation or other anti-tumor therapy
Treatment with other investigational agents within the prior 7 days prior to the 1st dose of AbGn-168H (neihulizumab)
Patient should not be part of another trial testing other investigational agents or devices
Patients may not be receiving any other investigational agents or any concomitant antineoplastic therapy, with the exception of androgen ablating agents (for patients with prior prostate cancer)
Patient must not have received treatment with other investigational agents within the last 4 weeks
Patients must have discontinued immunotherapy or other systemic therapy including investigational agents at least 4 weeks prior to entering the study and have recovered from adverse events due to those agents. Patients must agree to not receive any other investigational agents during study participation.
Subjects who have received investigational agents must wait at least 4 weeks
Patients may not receive any other anti-neoplastic or investigational agents within 3 weeks of study enrollment; patients may not be receiving any other investigational agents during treatment on protocol
Administration of any investigational agents within 30 days before study entry
Current receiving any other anti-neoplastic investigational agents
Current therapy with other investigational agents.
Subjects who have received any other investigational agents within 30 days of first lithium dose
Prior anti-leukemia therapy within 14 days of enrollment for classical cytotoxic agents, and within 5x the half-life for other investigational agents
Chemotherapy, biological therapy or investigational agents (except EGFR TKIs) within 4 weeks
Receiving any other investigational agents simultaneously or within 3 weeks following ablation procedure
Patients may not be receiving any other investigational agents; a minimum 4 week “washout” period is required
Use of investigational device or agents within 2 weeks of enrollment date.
Investigational agents/therapies
Investigational agents within 4 weeks of randomization.
Use of other investigational agents within 6 weeks of day 1 of protocol therapy
Participants receiving any other investigational or commercial agents or therapies administered with the intention to treat their malignancy within 14 days of first receipt of study drug, with the exception of hydroxyurea as defined in protocol
Investigational agents within 4 weeks before start of study therapy
Treatment less than two weeks prior to enrollment with other systemic experimental therapies or antineoplastic agents, with the exception of hydroxyurea and intrathecal chemotherapeutic agents
Patients who are receiving any androgens, estrogens or progestational agents, or who received any of these agents within the 6 months prior to evaluation will not be eligible
Investigational agents within 4 weeks of initial study treatment.
Patients may not use any of the following therapies during the study:\r\n* Any non-study anti-cancer agent (investigational or non-investigational)\r\n* Any other investigational agents\r\n* Any other (non-CA184024 related) CTLA-4 inhibitors or agonists\r\n* CD137 agonists\r\n* Immunosuppressive agents\r\n* Chronic systemic corticosteroids\r\n* Any non-oncology vaccine therapies used for the prevention of infectious diseases (for up to 30 days prior to or after any dose of study drug)
Patient is currently receiving or has received within the last month prior to Cycle 1 Day 1 (6 weeks for nitrosoureas, mitomycin-C, and liposomal doxorubicin) other chemotherapeutic, hormonal, or investigational anti-cancer agents with the exception of gonadal suppression agents and bisphosphonates for osteoporosis and skeletal metastases which may be continued while on study
Use of investigational agents, with the exception of gemtuzumab ozogamicin, within 30 days
Systemic anticancer treatment (including investigational agents) or radiotherapy less than 2 weeks before the first dose of study treatment (<=4 weeks for large molecule agents).
No restrictions on use of other investigational agents
Current or anticipated use of other investigational agents
No restrictions regarding use of other investigational agents
Patients must not have received any investigational agents within 30 days prior to commencing study treatment
Patients who are receiving other investigational agents will be permitted on study, at the discretion of the principal investigator
Participants who received any other chronic (defined as more than 50% of the time in the last 6 months) systemic immunomodulatory agents (replacement doses of steroids for adrenal insufficiency are permitted or treatment with prednisone =< 5 mg/day); receipt of investigational agents within the 4 weeks before randomization enrollment, other than investigational antiretroviral agents for HIV and investigational or approved agents for hepatitis C, are also exclusionary
Use of any other investigational agents =< 12 weeks prior to pre-registration
Current use of any other investigational agents
Active use of any other investigational agents
Current use of any other investigational agents
Current use of any other investigational agents
Current use of any other investigational agents
Receipt of any other investigational agents =< 3 months prior to randomization, except innocuous agents with no known interaction with the study agents (e.g., standard dose multivitamins or topical agents for limited skin conditions), at the discretion of the protocol lead investigator at each participating site
Individual may not be receiving any other investigational agents, antiplatelet agents (e.g. aspirin, clopidogrel [Plavix or others]), anticoagulants (e.g. heparin or heparinoids, Coumadin, or others), methotrexate, lithium
Receiving any other investigational agent =< 3 months prior to registration/randomization, except innocuous agents with no known interaction with the study agent (e.g., standard dose multivitamins or topical agents for limited skin conditions)
Patients may not be receiving any other investigational agents; any prior investigational therapeutic products must be stopped at least 28 days (4 week washout) prior to treatment start
Ongoing therapy with other investigational agents
Have received other investigational agents within the past 3 months (preceding the time of registration)
Receipt of any investigational agents within 30 days prior to commencing study treatment
Participants may not receive any other investigational agents within 30 days of enrollment nor during study participation
There will be no restrictions regarding use of other investigational agents
There will be no restrictions regarding use of other investigational agents
Other on-going cancer therapy or investigational agents (except MVT-5873 )
Patients must not receive any other investigational agents while on study
Patients should not be taking other investigational agents
Current use of any investigational agents
Subject has had no use of investigational agents, with the exception of FLT3 inhibiting agents during induction and/or consolidation therapy, within the prior 4 weeks.
Patients should not be taking other investigational agents
Current receipt of any other investigational agents or any additional anti-cancer agents for this or any other disease
At the time of registration, all subjects must be removed >= 28 days from any investigational agents
Ongoing treatment with any other investigational agents
Receipt of any other investigational agents or any additional anti-cancer agents
Treatment with other investigational agents (defined as not used in accordance with the approved indication) within 4 weeks of Day 1
Patients who are receiving any other investigational agents; a minimum of 4 weeks wash-out period is required for eligibility; please contact principal investigator, Dr. Swati Kulkarni for further clarification
Treatment with other investigational agents less than 14 days prior to study entry.
